GleamWall
中文EN

IMNN Imunon, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.78M$11.64M
SG&A expense$6.87M$7.49M
Operating income-$14.65M-$19.13M
Pretax income$14.50M$18.60M
Net income-$14.50M-$18.62M
EBITDA-$14.36M-$18.89M
EPS (basic)-6.83-16.94
EPS (diluted)-6.83-16.94
Weighted avg. shares (diluted)2.12M1.10M
Balance sheet
Cash & equivalents$8.78M$5.87M
Current assets$10.72M$8.01M
PP&E, net$529,936$541,272
Total assets$12.29M$9.72M
Current liabilities$4.62M$4.79M
Total liabilities$5.23M$5.47M
Shareholders' equity$7.06M$4.24M
Shares outstanding3.42M966,712
Cash flow statement
Operating cash flow-$13.90M-$18.85M
Capital expenditure$280,572$29,541
Free cash flow-$14.18M-$18.88M
Investing cash flow-$280,572$9.83M
Financing cash flow$17.09M$9.06M
Depreciation & amortization$291,908$240,175
Stock-based compensation$127,374$477,256

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.